Astragalus, a traditional Chinese herb, contains a plant-based compound known as TA-65 that has the potential to improve the outcome of heart attack patients, according to a study at Newcastle University in the UK.
The study found that TA-65 significantly reduces inflammation, and unlike current heart treatments, does not negatively impact immunity.
The study was conducted on patients aged 65 and over who had recently suffered a heart attack.
Patients were given either a placebo or TA-65 for over a year, and their blood was measured at baseline, six months, and a year to assess the outcomes.
Participants were also regularly reviewed in the clinic to check for any side effects.
The results showed that when patients were treated with the drug, they experienced far fewer complications following their heart attack, such as chest or joint pains.
In addition, TA-65 increased lymphocytes, improving the immunity of patients. It also reduced inflammation by up to 62%, which is considered a key treatment target following a heart attack for patients.
The team says it has become widely recognized that inflammation plays a key role in the formation, progression, and rupture of a coronary plaque, which induces heart attack, but, importantly, it is also a major risk factor for further complications.
Reducing inflammation is, therefore, considered a key treatment target following a heart attack for patients, and our study showed that TA-65 reduced inflammation by up to 62%.
TA-65 is a patented, plant-based compound isolated from Astragalus, a traditional Chinese medicine that has been used for thousands of years.
It helps maintain or rebuild telomeres, and those who received the drug had few adverse effects following their heart attack.
In fact, they showed 30% fewer adverse effects than the group given the dummy drug.
While some potent anti-inflammatory drugs have been shown to improve outcomes after heart attacks, they result in suppression of the immune system and increase the risk of severe infections.
In contrast, the widely available drug TA-65 reduces inflammation but appears to improve immunity by increasing a patient’s immune cells.
The study was carried out on a small sample of 90 patients, and the researchers would like to follow up with a larger study to confirm the results.
Further research will focus on whether TA-65 reduces adverse cardiac events, such as more heart attacks or even death.
The researchers hope that their study will pave the way for new treatment options for heart attack patients, particularly older patients who may not tolerate current cardiovascular treatments well.
By harnessing the power of plant-based compounds, they believe that they can improve the health outcomes of patients and reduce the risk of further complications.
To summarize, TA-65, a plant-based compound isolated from Astragalus, has the potential to improve the outcome of heart attack patients.
It reduces inflammation and improves immunity without negatively impacting the immune system.
While the study was carried out on a small sample, the researchers hope to conduct a larger study to confirm the results and explore the potential of TA-65 as a treatment option for heart attack patients.
If you care about heart health, please read studies about how eating eggs can help reduce heart disease risk, and scientists find new way to heal heart muscle.
For more information about health, please see recent studies about how drinking milk affects risks of heart disease and cancer, and results showing how COVID-19 damages the heart.
The study was conducted by Bilal Bawamia et al and published in GeroScience.
Copyright © 2023 Knowridge Science Report. All rights reserved.
